SOURCE: Spotlight Innovation Inc.

Spotlight Innovation Inc.

August 14, 2015 13:09 ET

Spotlight Innovation CEO to Speak at BioNetwork West Partnering Summit October 26-28, 2015

WEST DES MOINES, IA--(Marketwired - Aug 14, 2015) - Spotlight Innovation Inc. (OTCQB: STLT) announces today that its CEO Cristopher Grunewald is a scheduled speaker at the BioNetwork West Partnering Summit to be held at the Ritz-Carlton, Laguna Niguel, CA, October 26th through the 28th, 2015.

As a speaker at the conference, Mr. Grunewald will showcase Spotlight Innovation and its two subsidiary companies, Celtic Biotech and Memcine Pharmaceuticals. Celtic Biotech is developing therapies for solid cancers utilizing compounds derived from snake venoms. Memcine Pharmaceuticals is working to enhance vaccine efficacy utilizing its Immunoplex™ platform technology, which uses the body's naturally occurring targeting system to deliver vaccine components.

Cristopher Grunewald, President and CEO of Spotlight Innovation, said, "This event represents a great opportunity to connect with licensing professionals, decision makers and business development executives. I look forward to raising Spotlight Innovation's visibility, and establishing lasting relationships with these industry leaders."

To receive a Spotlight Innovation information kit or to schedule a one-on-one meeting with Cristopher Grunewald, contact Rudy Barrio at DresnerAllenCaron by calling 1-212-691-8087 or sending an email to

About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) identifies, acquires and incubates companies that have unique intellectual property (IP) in the medical sector. The Company has relationships with the nation's leading academic and institutional IP developers, and locates promising IP technologies with potential for market share capture. With strong support, development, resources and strategic planning expertise, we believe we can develop IP that will have a positive effect on healthcare. We intend to partner with proven sector leaders on commercialization once technologies are fully developed. Additional information available at

About Celtic Biotech Iowa, Inc.
Celtic Biotech Iowa, Inc., a subsidiary of Spotlight Innovation Inc., is developing novel, clinical trial-phase products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality-of-life for cancer patients. Additional information available at

About Memcine Pharmaceuticals Inc.
Memcine Pharmaceuticals Inc. is an early-stage biotech company focused on enhancing vaccine efficacy to improve human and animal health globally. Memcine's Immunoplex™ technology platform uses the body's naturally occurring targeting system to deliver vaccine components. The current portfolio of potential infectious disease vaccine targets includes influenza, HepB, and Ebola. Memcine Pharmaceuticals has also conducted pre-clinical experiments in a mouse model of breast cancer, where the vaccine technology showed considerable promise as a therapeutic treatment. Additional information available at

Forward Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Contact Information